Research
Metabolic adaptation
GLP-1 RAs may provide benefits for other obesity-related comorbidities, including hypertension and cardiovascular disease.
Practitioners should be aware of the potential for GLP-1 RAs to address comorbidities in obese OSA patients.
StrongSupportsmedium confidence
GLP-1 RAs may provide benefits for other obesity-related comorbidities, including hypertension and cardiovascular disease, which are commonly associated with OSA.
Why this rating
The claim is supported by the narrative review's focus on GLP-1 RAs and their effects.
Source
Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review
Ali El-Solh et al. · Expert Opinion on Pharmacotherapy · 2024
DOI 10.1080/14656566.2024.2437525
reviewCited 21×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1 RAs) may improve obstructive sleep apnea (OSA) symptoms by reducing fat deposition around the upper airway and decreasing systemic inflammation.Strong
- GLP-1 RAs may enhance traditional OSA treatments, offering an integrated approach targeting the root cause of obesity in OSA.Strong
Related findings · Metabolic adaptation
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →